Amgen teases ‘promising’ section 2 information for intently watched KRAS prospect


Simply two weeks after unveiling full information from its section 1 program, Amgen’s KRAS inhibitor is again with extra. The Massive Biotech teased outcomes from a section 2 research that it says echo the efficacy seen in its intently watched section 1 trial.

Whereas the sooner research examined 4 dose ranges of the drug, sotorasib, the section 2 research examined the highest dose of the drug in 129 sufferers with non-small cell lung most cancers (NSCLC) whose illness had worsened regardless of attempting a median of two different remedies. Amgen saved specifics below wraps however stated Monday afternoon that the brand new information have been “constant” with the 35% response fee seen in 34 sufferers who obtained the highest dose within the earlier trial.

On the information cutoff, greater than half of the sufferers have been nonetheless being handled, and different efficacy measures, like how lengthy sufferers’ responses lasted, appeared “promising,”  Amgen stated. The corporate plans to element the outcomes on the World Congress on Lung Most cancers (WCLC) in January 2021, and it appears to be like ahead to discussing them with the FDA and different regulators “to find out one of the best path ahead for sotorasib as a possible remedy for sufferers with NSCLC harboring the KRAS G12C mutation,” Amgen R&D chief David Reese, M.D., stated in a press release.


Contained in the COVID-SeroIndex – Assay Design and Efficiency

Be part of a panel of specialists as they focus on the rigor concerned in optimizing and scaling a reproducible serological assay for COVID-19.

A section three research pitting sotorasib towards chemo drug docetaxel, in the meantime, is already underway.

RELATED: ESMO: Amgen’s KRAS drug tackles 32% of lung cancers—and that is only the start

Regardless of the paucity of data on the section 2 outcomes, business watchers are optimistic. Jefferies analyst Michael Yee expects an FDA submitting quickly, he wrote in a notice to purchasers, whereas Evercore ISI analyst Umer Raffat extrapolated his technique to some conclusions and deemed the info “v good.”

Primarily based on when the trial completed enrolling—January of this yr—and when submissions closed for WCLC, Raffat inferred the info cutoff to be this previous August.

Recruiting “was ‘speedy’ as per AMGN, and by my math, recruiting was executed between” late August of final yr and early January 2020, he wrote in an investor notice on Monday, including that the “Overwhelming majority of the responses on this first half of pts have kicked in by end-Dec.” In different phrases, there have been eight months of follow-up by the point Amgen’s summary submission was due in late August, he figured.

As for sufferers enrolled later, in November and December of final yr, Raffat figured the drug would have began shrinking tumors by January or February, so “even these responders are 7+ months of comply with up by at this time.”


Please enter your comment!
Please enter your name here